View source for Asenapine

{{drugbox
| IUPAC_name        = (3a''S'',12b''S'')-5-Chloro-2,3,3a,12b-tetrahydro-<br>2-methyl-1''H''-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
| image             = Asenapine.png
| CAS_number        = 65576-45-6
| ATC_prefix        = 
| ATC_suffix        = 
| PubChem           = 163091
| DrugBank          = 
| C = 17 | H = 16 | Cl = 1 | N = 1 | O = 1
| molecular_weight  = 285.77 g/mol
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         = 
| pregnancy_AU      =  <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      =  <!-- A / B            / C / D / X -->
| pregnancy_category=  
| legal_AU          =  <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA          =  <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK          =  <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US          =  <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status      = 
| routes_of_administration = 
}}

'''Asenapine''' is a new [[5-HT2A receptor|5-HT<sub>2A</sub>-]] and [[dopamine receptor|D2-receptor]] [[antagonist]] under development for the treatment of [[schizophrenia]] and acute mania associated with [[bipolar disorder]] by [[Schering-Plough]] after its [[November 19]], [[2007]] combination with  [[Organon International]].  Development of the drug, through [[Phase III]] trials, began while Organon was still a part of [[Akzo Nobel]].<ref name="GEN200706">{{cite news
 | title = Bipolar Disorder | work = Clinical Trials Update
 | publisher = Genetic Engineering & Biotechnology News | pages = 52,55 | date = 2007-06-15 | accessdate = 2007-12-16
}}</ref>  Preliminary data indicate that it has minimal anticholinergic and cardiovascular side effects, as well as minimal weight gain. Over 3000 patients have participated in [[clinical trial]]s of asenapine, and the [[Food and Drug Administration|FDA]] accepted the manufacturer's [[New Drug Application|NDA]] on [[November 26]], [[2007]] for standard review. <ref>{{cite press release
| title = Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
| publisher = Schering-Plough
| date = [[2007-11-26]]
| url = http://www.schering-plough.com/schering_plough/news/release.jsp?releaseID=1080771
| accessdate = 2007-11-26 }})</ref>

Asenapine belongs to a class of neuroleptics known as "[[atypical antipsychotics]]", which have, over the last two decades, become increasingly popular alternatives to "[[typical antipsychotics]]", such as [[haloperidol]]. The manufacturers of asanapine refer to it as a "new generation" or "second generation" atypical antipsychotic.

Other atypical antipsychotics include [[aripiprazole]], [[olanzapine]], [[quetiapine]], [[risperidone]], and [[ziprasidone]].


==Notes==

<references />

==External links==

===Commercial===
* [http://www.organon.com/ Organon website]

===Third-party===
* [http://www.medicalnewstoday.com/medicalnews.php?newsid=57683 Organon Continues With The Development Of Asenapine For Schizophrenia And Acute Mania Associated With Bipolar I Disorder]

[[Category:Receptor modulators]]
{{Antipsychotics}}

<!--Categories-->
[[Category:Atypical antipsychotics]]



{{pharma-stub}}